Take This Into Account Before Investing in PHG

Koninklijke Philips logged a 32.6% change during today's morning session, and is now trading at a price of $27.93 per share. The S&P 500 index moved 0.0%. PHG's trading volume is 4,706,264 compared to the stock's average volume of 1,009,935.

Koninklijke Philips trades 34.99% away from its average analyst target price of $20.69 per share. The 3 analysts following the stock have set target prices ranging from $18.69 to $22.0, and on average have given Koninklijke Philips a rating of underperform.

If you are considering an investment in PHG, you'll want to know the following:

  • Koninklijke Philips has moved 1.2% over the last year, and the S&P 500 logged a change of 22.4%

  • Based on its trailing earnings per share of -0.51, Koninklijke Philips has a trailing 12 month Price to Earnings (P/E) ratio of -54.8 while the S&P 500 average is 15.97

  • PHG has a forward P/E ratio of 16.5 based on its forward 12 month price to earnings (EPS) of $1.69 per share

  • The company has a price to earnings growth (PEG) ratio of 0.82 — a number near or below 1 signifying that Koninklijke Philips is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 2.1 compared to its sector average of 4.08

  • Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally.

  • Based in Amsterdam, the company has 69,656 full time employees and a market cap of $25.32 Billion. Koninklijke Philips currently returns an annual dividend yield of 4.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.